Archives

Ozempic Shows a Possible Hidden Effect on Epilepsy Risk

GLP-1 drugs like Ozempic, Trulicity and Victoza were associated with a slightly lower likelihood of developing epilepsy in a large group of people with type 2 diabetes. GLP-1 drugs may be connected to a lower chance of developing epilepsy in people with type 2 diabetes, offering an intriguing early signal for researchers. Participants who used […]

Bone Fractures Down With GLP-1 Drugs in the Picture

(MedPage Today) — Beyond their established cardiometabolic benefits, GLP-1 receptor agonists also may be tied to improved bone health, based on an observational report. Adults with type 2 diabetes on GLP-1 agonists tended to have small but significant…

Can NVO Defend Its Obesity Lead as GLP-1 Competition Intensifies?

Novo Nordisk NVO is a dominant player in the cardiometabolic space, marketing its blockbuster semaglutide-based (GLP-1) drugs — Ozempic (for diabetes) and Wegovy (for obesity). Despite being NVO’s key growth drivers, sales momentum for both drugs has slowed in recent quarters due to pricing pressure, intensifying GLP-1 competition from Eli Lilly LLY, foreign exchange headwinds, and […]

Pharmaceutics, Vol. 17, Pages 1596: Oral Treatment of Obesity by GLP-1 and Its Analogs

Pharmaceutics, Vol. 17, Pages 1596: Oral Treatment of Obesity by GLP-1 and Its Analogs Pharmaceutics doi: 10.3390/pharmaceutics17121596 Authors: Natasa Holler Ivana Ruseska Anna-Laurence Schachner-Nedherer Andreas Zimmer Christina Petschacher Obesity is a multifaceted disease that significantly increases the risk of various chronic conditions. GLP-1R (co)-agonists first emerged as therapeutics for treatment of type 2 diabetes mellitus […]

Argus Downgrades Novo Nordisk A/S (NVO) to Hold From Buy

Novo Nordisk A/S (NYSE:NVO) is one of the best pharma stocks to invest in. Argus analyst Jasper Hellweg downgraded Novo Nordisk A/S (NYSE:NVO) to Hold from Buy on December 8, without assigning a price target. The analyst told investors in a research note that the company is experiencing a drop in marketshare in its GLP-1 drug […]

Antioxidants, Vol. 14, Pages 1484: BiombalanceTM: A Specific Oligomeric Procyanidin-Rich Grape Seed Extract as Multifunctional Ingredient Integrating Antibacterial, Antioxidant, and Anti-Inflammatory Activities with Beneficial Gut–Brain Axis Modulation

Antioxidants, Vol. 14, Pages 1484: BiombalanceTM: A Specific Oligomeric Procyanidin-Rich Grape Seed Extract as Multifunctional Ingredient Integrating Antibacterial, Antioxidant, and Anti-Inflammatory Activities with Beneficial Gut–Brain Axis Modulation Antioxidants doi: 10.3390/antiox14121484 Authors: Mohamed Mokrani Amandine Brochot Maria C. Urdaci Polyphenols, as natural compounds abundant in plant-derived foods, have been recognised for their human health benefits. This […]

Chronic semaglutide treatment enhances the incentive motivational value of a small food reward and associated cue in male and female rats

Rationale: Glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide, are increasingly utilized in clinical practice due to their efficacy in promoting sustained weight loss following chronic administration. While acute treatment with GLP-1 receptor agonists has been shown to suppress food intake and reward-seeking behaviors in rodent models, the impact of prolonged exposure on preclinical measures […]